# Robert J. de Knegt

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-j-de-knegt/

## Facts

| Field | Value |
| --- | --- |
| Citations | 12,553 |
| Field | Liver Disease Diagnosis and Treatment |
| h-index | 56 |
| i10-index | 182 |
| Last Known Institution | Erasmus MC |
| OpenAlex ID | https://openalex.org/A5018450847 |
| ORCID iD | 0000-0003-0934-6975 |
| Works | 392 |

## Researcher papers

- [Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis](https://scholariq.org/papers/association-between-sustained-virological-response-and-all-cause-mortality-among/)
- [EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version)](https://scholariq.org/papers/efsumb-guidelines-and-recommendations-on-the-clinical-use-of-liver-ultrasound/)
- [Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases](https://scholariq.org/papers/population-screening-for-liver-fibrosis-toward-early-diagnosis-and-intervention/)
- [Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus](https://scholariq.org/papers/increased-risk-of-hepatocellular-carcinoma-among-patients-with-hepatitis-c/)
- [Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication](https://scholariq.org/papers/risk-of-cirrhosis-related-complications-in-patients-with-advanced-fibrosis/)
- [Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults](https://scholariq.org/papers/estimating-global-prevalence-of-metabolic-dysfunction-associated-fatty-liver/)
- [EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version)](https://scholariq.org/papers/efsumb-guidelines-and-recommendations-on-the-clinical-use-of-liver-ultrasound-2/)
- [Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians](https://scholariq.org/papers/entecavir-treatment-does-not-eliminate-the-risk-of-hepatocellular-carcinoma-in/)
- [An international multidisciplinary consensus statement on MAFLD and the risk of CVD](https://scholariq.org/papers/an-international-multidisciplinary-consensus-statement-on-mafld-and-the-risk-of/)
- [Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study](https://scholariq.org/papers/development-validation-and-prognostic-evaluation-of-a-risk-score-for-long-term/)
- [Integrating Gut Microbiome and Metabolome to Gain Insight into Metabolic Dysfunction-Associated Steatotic Liver Disease](https://scholariq.org/papers/integrating-gut-microbiome-and-metabolome-to-gain-insight-into-metabolic/)

## Researcher topics

- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [Hepatitis B Virus Studies](https://scholariq.org/topics/hepatitis-b-virus-studies/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)

## Researcher university

- [Erasmus MC](https://scholariq.org/institutions/erasmus-mc/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.